Ozempic unboxing videos: what they show and what they skip
Quick answer
The creator demonstrates subcutaneous injection of semaglutide at the 0.25 mg starting dose into the thigh using an Ozempic autoinjector pen, consistent with standard titration initiation protocol. She correctly identifies the injection site and button-hold technique, though her description of click-based dose confirmation omits the essential step of visually verifying the dose counter returns to zero. The video shows disposal of the used needle in a sharps container, which aligns with UK safe disposal requirements for sharps waste.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @chezziemai actually say?
This is a reshared unboxing of a first Ozempic pen. The creator walks through the pen components, describes screwing on a needle, selecting "0.25" as the dose, injecting into the thigh, holding the button for a count of 10, and listening for a clicking sound as confirmation the dose delivered. She notes it "didn't hurt" and says she'll repeat it "next Wednesday."
There's no medical advice being dispensed here, no weight loss claims beyond the hashtags, and no promises about outcomes. This is genuinely just someone showing what opening a prescription medication looks like for the first time. That context matters when evaluating what's accurate and what's worth correcting.
Does the science back this up?
The core injection mechanics she describes are broadly consistent with Novo Nordisk's own prescribing guidance, with one meaningful gap. Semaglutide at 0.25 mg weekly is the standard starting dose in both the SUSTAIN and STEP trial programs, used specifically to reduce gastrointestinal side effects before titrating upward.
Injecting into the thigh is one of the three approved subcutaneous sites, alongside the abdomen and upper arm. The instruction to hold the button down and count slowly is also correct. Novo Nordisk's patient instructions specify holding for at least 6 seconds after the click to ensure full dose delivery. The clicking mechanism is a dose counter, not purely a delivery confirmation, which is worth clarifying. Research published by Davies et al. (2021, Diabetes Care) confirmed that subcutaneous semaglutide delivery via autoinjector pen produces consistent pharmacokinetics across injection sites.
What did they get wrong (or right)?
She got the starting dose right. She got the injection site right. She got the needle attachment process roughly right, though her description of "screwing it up like a screw" is imprecise enough that a first-time user copying her technique could under-tighten the needle and risk a leaking or dislodged needle mid-injection.
The bigger issue is the "count to 10 and then pull it out, count to 10 slowly" instruction. The official guidance is to hold for at least 6 seconds after the dose counter returns to zero, not a full 10-count post-removal. Counting after removal serves no clinical purpose and is not in Novo Nordisk's instructions. It's a minor error but could confuse new users.
She also describes the click as confirmation the injection "has been done," which is partly right. The click indicates the dose counter has moved, but visual confirmation that the counter reads zero is the actual verification step. Users who rely only on sound could miss an incomplete dose.
What should you actually know?
Ozempic (semaglutide 1 mg/0.5 ml) pens are licensed in the UK for type 2 diabetes management. Wegovy (semaglutide 2.4 mg) is the licensed weight management formulation. These are different products with different licensed indications, dosing schedules, and pen configurations. The hashtags here say weight loss, but Ozempic's UK licence does not cover weight management as a standalone indication.
If you're starting a GLP-1 medication for the first time, watching a TikTok unboxing is not a substitute for reading the patient information leaflet or speaking with your prescriber. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed 14.9% mean body weight reduction with semaglutide 2.4 mg over 68 weeks, but that was with structured lifestyle intervention, not injection technique borrowed from social media.
- Always confirm the dose counter reads zero after injection, not just listen for a click.
- Rotate injection sites between weeks to reduce lipohypertrophy risk.
- Needle disposal in a sharps bin is legally required in the UK, which she does mention correctly.
Bottom line
This video is more accurate than most GLP-1 content on TikTok. The creator is not making inflated claims, selling anything, or giving medical advice. The technique she shows is mostly correct. But "mostly correct" injection guidance, shared to 4,100 viewers who may be starting their own pens, is worth scrutinising. The specific errors around dose confirmation and needle attachment are small enough to seem pedantic until someone draws back an incomplete dose and doesn't know why.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Ozempic unboxing videos: what they show and what they skip, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The creator demonstrates subcutaneous injection of semaglutide at the 0.
FormBlends verdict
The creator demonstrates subcutaneous injection of semaglutide at the 0.25 mg starting dose into the thigh using an Ozempic autoinjector pen, consistent with standard titration initiation protocol. She correctly identifies the injection site and button-hold technique, though her description of click-based dose confirmation omits the essential step of visually verifying the dose counter returns to zero. The video shows disposal of the used needle in a sharps container, which aligns with UK safe disposal requirements for sharps waste.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator demonstrates subcutaneous injection of semaglutide at the 0.25 mg starting dose into the thigh using an Ozempic autoinjector pen, consistent with standard titration initiation protocol. She correctly identifies the injection site and button-hold technique, though her description of click-based dose confirmation omits the essential step of visually verifying the dose counter returns to zero. The video shows disposal of the used needle in a sharps container, which aligns with UK safe disposal requirements for sharps waste.
- 0.25 mg once weekly is the correct semaglutide starting dose, used for at least 4 weeks before titration per SUSTAIN trial protocols.
- The Ozempic autoinjector pen contains 4 doses per pen, not a single-use device, which the creator correctly identifies.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- 0.25 mg once weekly is the correct semaglutide starting dose, used for at least 4 weeks before titration per SUSTAIN trial protocols.
- The Ozempic autoinjector pen contains 4 doses per pen, not a single-use device, which the creator correctly identifies.
- Dose delivery confirmation requires visual verification that the dose counter reads zero, not just listening for a click, per Novo Nordisk prescribing guidance.
- The thigh is a valid injection site. Davies et al. (2021, Diabetes Care) confirmed equivalent absorption across thigh, abdomen, and upper arm.
- Ozempic holds a UK licence for type 2 diabetes, not standalone weight management. Wegovy is the licensed weight management formulation of semaglutide.
- Wilding et al. (2021, NEJM) found 14.9% mean weight reduction with semaglutide 2.4 mg over 68 weeks, achieved alongside structured lifestyle intervention, not injection technique alone.
- Used needles must be disposed of in an approved sharps container under UK regulations, a step the creator correctly demonstrates.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Cheri · TikTok creator
4.1K views on this video
#onthisday reshare of unboxing my first ozempic pen #weightloss #weightlosstransformation #weightlossprogress #fyp #foryourpage #weightlossjourney #weightlossjourneyuk #lostweight #weightlosscheck #weightlossadvice #weightlossmotivation #weightlossmotivationuk
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Cheri, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.